KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Jazz Pharmaceuticals (JAZZ) Non-Current Deffered Revenue: 2009-2022

Historic Non-Current Deffered Revenue for Jazz Pharmaceuticals (JAZZ) over the last 14 years, with Sep 2022 value amounting to $116,000.

  • Jazz Pharmaceuticals' Non-Current Deffered Revenue fell 88.24% to $116,000 in Q3 2022 from the same period last year, while for Sep 2022 it was $116,000, marking a year-over-year decrease of 88.24%. This contributed to the annual value of $463,000 for FY2021, which is 80.00% down from last year.
  • According to the latest figures from Q3 2022, Jazz Pharmaceuticals' Non-Current Deffered Revenue is $116,000, which was down 49.78% from $231,000 recorded in Q2 2022.
  • In the past 5 years, Jazz Pharmaceuticals' Non-Current Deffered Revenue ranged from a high of $13.6 million in Q1 2018 and a low of $116,000 during Q3 2022.
  • For the 3-year period, Jazz Pharmaceuticals' Non-Current Deffered Revenue averaged around $1.7 million, with its median value being $1.5 million (2021).
  • Data for Jazz Pharmaceuticals' Non-Current Deffered Revenue shows a maximum YoY slumped of 88.24% (in 2022) over the last 5 years.
  • Over the past 5 years, Jazz Pharmaceuticals' Non-Current Deffered Revenue (Quarterly) stood at $9.6 million in 2018, then tumbled by 49.26% to $4.9 million in 2019, then slumped by 52.38% to $2.3 million in 2020, then plummeted by 80.00% to $463,000 in 2021, then slumped by 88.24% to $116,000 in 2022.
  • Its Non-Current Deffered Revenue was $116,000 in Q3 2022, compared to $231,000 in Q2 2022 and $347,000 in Q1 2022.